Search for a command to run...
We appreciate the interest in our findings and would like to thank Dr. Lattanzi for the insightful comments on our recent publication titled “Ictal–Interictal Continuum and Status Epilepticus: Two Sides of the Same Coin? A Prospective Magnetic Resonance Imaging Study.”1 We fully agree with the importance of an etiology-driven approach for the diagnosis and management of both ictal–interictal continuum (IIC) and status epilepticus (SE). Prior to this work, our group had also highlighted and suggested this framework in a previous letter to the editor,2 emphasizing the potential of such an approach to refine diagnostic accuracy and prognostic stratification. We also agree that a more granular classification of etiologies would ideally provide additional insights and eventually identify additional valuable clusters. However, due to sample size limitations in our cohort of patients with either nonconvulsive SE or IIC (N = 133), etiologies were grouped into three broad categories for the latent cluster analysis. Nevertheless, we prioritized distinguishing acute primary central nervous system pathology from acute-triggered epilepsy, which have distinct prognostic implications3 and therefore warrant separate analysis. We would also like to emphasize that the updated classification with different etiological subgroups proposed by Lattanzi et al.3 has not yet been formally validated, and further validation in another cohort is warranted to make such assumptions. Ideally, future studies with larger cohorts integrating neurophysiology, clinical features, and neuroimaging4, 5 should explore more detailed subcategorization within each etiological group to better capture electroclinical heterogeneity and optimize individualized patient management. Open Access funding provided by Paracelsus Medizinische Privatuniversitat/KEMÖ. Pilar Bosque-Varela has received travel grants and honoraria from UCB. Eugen Trinka reports personal fees from EVER Pharma, Marinus, Arvelle, Angelini, Argenx, Alexion, Medtronic, Bial–Portela & Cª, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova, Eisai, UCB, Biogen, Sanofi, Jazz Pharmaceuticals, Stoke Therapeutics, and Actavis. He is codirector of the European Consortium on Epilepsy Trials. His institution has received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Osterreichischer Fond zur Wissenschaftsforderung, Bundesministerium für Wissenschaft und Forschung, and Jubiläumsfond der Österreichischen Nationalbank. None was related to the presented work. Giorgi Kuchukhidze has received research grants from Austrian Research Fund (project number KLI 969); and travel grants and honoraria from UCB, Jazz Pharmaceuticals, and Novartis. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.